The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.
News & Analysis: Epizyme
If you have cash to spare, these cancer stocks are set to soar.
EPZM earnings call for the period ending March 31, 2020.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.
Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.
On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts tons of institutional investor support.
EPZM earnings call for the period ending December 31, 2019.
The pharma company released full-year 2019 operating results.
Tazemetostat is already approved to treat advanced epithelioid sarcoma; the biotech is now pursing an approval for advanced follicular lymphoma.